SUBSCRIBE
SUBSCRIBE
News   FDA

FDA Extends Review of Pfizer Inc. (JOBS) Osteoporosis Drug

October 22, 2008 | 
1 min read
WASHINGTON, Oct 21 (Reuters) - U.S. regulators have extended by three months their review of a proposed osteoporosis drug from Pfizer Inc to study the pill in more depth, a company spokeswoman said on Tuesday.
FDA Approvals Regulatory
Pfizer
MORE ON THIS TOPIC
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Rare diseases
Deaths reported after treatment with Neurocrine’s approved Prader-Willi drug
August 12, 2026
 · 
3 min read
 · 
Annalee Armstrong
FDA
Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
August 12, 2026
 · 
1 min read
 · 
Jef Akst
Cross icon. Reject, decline concept. Hand Mouse Cursor Clicks the Button. Pointer Push Press
Manufacturing
FDA rejects ITM Isotope’s radiopharma therapy over manufacturing issues
August 11, 2026
 · 
1 min read
 · 
Gabrielle Masson
Email envelope with warning sign on white background
Manufacturing
Scholar Rock rejigs approval filing after FDA flags violations at Novo plant
August 11, 2026
 · 
2 min read
 · 
Nick Paul Taylor